All In Biotech

Drug Trial Radar · NCT06769048

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

JADE: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-masked, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of BI 1584862

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Actual

Start

Jan 31, 2025

Primary completion

Dec 22, 2026

Study completion Jan 5, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose. This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group. Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.

Conditions

  • Geographic Atrophy

Interventions

  • Placebo-matching BI 1584862Drug

    Placebo-matching BI 1584862

  • BI 1584862Drug

    BI 1584862

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eyeTime frame: Up to week 50.

Locations

44 sites in 2 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Gilbert, Arizona

  • Associated Retina Consultants, Ltd.

    Phoenix, Arizona

  • Cameron Ria, LLC

    Phoenix, Arizona

  • Retina Macula Institute of Arizona

    Scottsdale, Arizona

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Global Research Management

    Glendale, California

  • Retina Associates of Southern California

    Huntington Beach, California

  • Retinal Consultants Medical Group, Inc

    Modesto, California

  • Northern California Retina Vitreous Associates MedicalGroup, Inc.

    Mountain View, California

  • Eye Research Foundation

    Newport Beach, California

  • Retina Consultants of San Diego

    Poway, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • Bay Area Retina Associates - Walnut Creek

    Walnut Creek, California

  • Retina Specialists of Colorado Research, LLC

    Denver, Colorado

  • Coastal Eye Surgeons

    Greenwich, Connecticut

  • Vitreo Retinal Associates - Gainesville

    Gainesville, Florida

  • MedEye Associates

    Miami, Florida

  • Eye Associates of Pinellas

    Pinellas Park, Florida

  • East Florida Eye Institute

    Stuart, Florida

  • Center for Retina and Macular Disease

    Winter Haven, Florida

  • Southeast Retina Center, PC

    Augusta, Georgia

  • Illinois Retina Associates - Oak Park

    Oak Park, Illinois

  • The Eye Care Institute

    Louisville, Kentucky

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • University of Missouri Health System

    Columbia, Missouri

  • NJRetina

    Teaneck, New Jersey

  • Verum Research, LLC

    Eugene, Oregon

  • Retina Northwest

    Portland, Oregon

  • EyeHealth Northwest

    Portland, Oregon

  • Mid Atlantic Retina - Wills Eye Hospital

    Philadelphia, Pennsylvania

  • Charleston Neuroscience Institute - Charleston

    Charleston, South Carolina

  • Tennessee Retina

    Nashville, Tennessee

  • Austin Clinical Research, LLC

    Austin, Texas

  • Retina Consultants of Texas - Beaumont

    Beaumont, Texas

  • Retina Foundation of the Southwest

    Dallas, Texas

  • Red River Research Partners, LLC - Plano

    Plano, Texas

  • Retinal Consultants of San Antonio

    San Antonio, Texas

  • Retina Consultants of Texas - Schertz

    Schertz, Texas

  • Retina Consultants of Texas-The Woodlands-67575

    The Woodlands, Texas

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.